Physician profile
Daniel P Mokry
NPI 1346209806
$6,248.17
in general payments reported to CMS, 2019-2025
21 companies · $4,641 in 2025
The $4,641 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $58.96 · 2021: $245 · 2022: $405 · 2023: $348 · 2024: $347 · 2025: $4,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,241 · Food and Beverage: $1,111 · Travel and Lodging: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,241.05 |
| Food and Beverage | $1,111.20 |
| Travel and Lodging | $984.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,375.76 | 2025 | |
| Astellas Pharma US INC | $548.18 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $438.10 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $128.41 | 2023-2025 | Myfembree, Gemtesa |
| Pacira Pharmaceuticals Incorporated | $114.99 | 2025 | Exparel |
| Ethicon US, LLC | $103.64 | 2021 | |
| Millicent US INC | $98.38 | 2019-2024 | Intrarosa, Femring |
| Roche Diagnostics Corporation | $80.53 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $56.42 | 2022-2024 | |
| Medtronic, INC. | $42.20 | 2025 | Truclear |
| Mylan Pharmaceuticals INC. | $42.03 | 2019-2022 | |
| Organon LLC | $38.75 | 2024-2025 | Jada System |
| Scynexis, INC. | $36.68 | 2022 | |
| Meditrina | $25.78 | 2025 | |
| Therapeuticsmd, INC. | $21.27 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $19.42 | 2019 | |
| Duchesnay USA Incorporated | $18.54 | 2020 | |
| Exeltis, USA INC. | $17.44 | 2019 | |
| Merck Sharp & Dohme LLC | $14.65 | 2019 | |
| Evofem Biosciences, INC. | $13.81 | 2024 | |
| Coopersurgical, INC. | $13.19 | 2023 | Summit Doppler |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mokry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.